Scarica l'app Stockscreener
5.695
6.02%
-0.365
Precedente Chiudi:
$6.06
Aprire:
$5.96
Volume 24 ore:
3,745
Relative Volume:
0.15
Capitalizzazione di mercato:
$7.44M
Reddito:
-
Utile/perdita netta:
$-57.11M
Rapporto P/E:
-0.3797
EPS:
-15
Flusso di cassa netto:
$-34.82M
1 W Prestazione:
-6.22%
1M Prestazione:
+6.95%
6M Prestazione:
-41.59%
1 anno Prestazione:
-70.84%
Intervallo 1D:
$5.50
$6.00
Intervallo di 1 settimana:
$5.50
$6.7509
Portata 52W:
$4.4701
$35.98
Apollomics Inc Stock (APLM) Company Profile
Confronta APLM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
5.695 | 7.44M | 0 | -57.11M | -34.82M | -15.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Apollomics Inc Borsa (APLM) Ultime notizie
New Age Metals (OTCMKTS:NMTLF) Trading 1.2% Higher – Here’s Why - Defense World
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 87.9% - Defense World
Orca Energy Group (OTCMKTS:ORXGF) Trading 1.4% Higher – What’s Next? - Defense World
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World
How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com
Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus
Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus
(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World
APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Apollomics Inc Azioni (APLM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
1.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):